Andrea Gloria Rotnitzky, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biometry | 7 | 2009 | 565 | 0.630 |
Why?
|
| Lead | 9 | 1996 | 880 | 0.500 |
Why?
|
| Data Interpretation, Statistical | 6 | 2018 | 2708 | 0.470 |
Why?
|
| Models, Statistical | 10 | 2018 | 5099 | 0.390 |
Why?
|
| Bone and Bones | 8 | 1999 | 2589 | 0.330 |
Why?
|
| AIDS Vaccines | 2 | 2013 | 900 | 0.240 |
Why?
|
| Spectrometry, X-Ray Emission | 5 | 1996 | 143 | 0.230 |
Why?
|
| Clinical Trials as Topic | 4 | 2013 | 8051 | 0.230 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2009 | 710 | 0.230 |
Why?
|
| Treatment Failure | 2 | 2008 | 2663 | 0.200 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2008 | 1903 | 0.200 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 1280 | 0.190 |
Why?
|
| ROC Curve | 1 | 2009 | 3623 | 0.190 |
Why?
|
| Probability | 5 | 2010 | 2482 | 0.180 |
Why?
|
| Likelihood Functions | 2 | 2018 | 993 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2008 | 10377 | 0.170 |
Why?
|
| Regression Analysis | 6 | 2018 | 6350 | 0.160 |
Why?
|
| Risperidone | 1 | 2001 | 383 | 0.160 |
Why?
|
| Lead Poisoning | 3 | 1999 | 323 | 0.160 |
Why?
|
| Odds Ratio | 2 | 2010 | 9682 | 0.150 |
Why?
|
| HIV Infections | 4 | 2013 | 17575 | 0.120 |
Why?
|
| Cohort Studies | 5 | 2017 | 41795 | 0.120 |
Why?
|
| Hematinics | 1 | 2017 | 282 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2010 | 22296 | 0.110 |
Why?
|
| Nonlinear Dynamics | 1 | 1997 | 494 | 0.110 |
Why?
|
| Research Design | 4 | 2012 | 6210 | 0.110 |
Why?
|
| Algorithms | 4 | 2010 | 14154 | 0.110 |
Why?
|
| Linear Models | 5 | 1997 | 5878 | 0.110 |
Why?
|
| Sampling Studies | 1 | 2013 | 616 | 0.100 |
Why?
|
| Occupations | 1 | 1994 | 519 | 0.100 |
Why?
|
| Biostatistics | 1 | 2013 | 165 | 0.100 |
Why?
|
| Patella | 4 | 1996 | 317 | 0.090 |
Why?
|
| Sensitivity and Specificity | 5 | 2008 | 14737 | 0.080 |
Why?
|
| Hemoglobins | 1 | 1994 | 1532 | 0.080 |
Why?
|
| Longitudinal Studies | 7 | 2010 | 14784 | 0.080 |
Why?
|
| Anemia | 1 | 2017 | 1519 | 0.070 |
Why?
|
| Mathematical Computing | 1 | 2007 | 142 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2013 | 6241 | 0.070 |
Why?
|
| Tibia | 4 | 1996 | 1075 | 0.070 |
Why?
|
| Occupational Diseases | 1 | 1995 | 1490 | 0.070 |
Why?
|
| Quality of Life | 1 | 2008 | 13503 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2008 | 2202 | 0.070 |
Why?
|
| Psychotic Disorders | 1 | 2001 | 3279 | 0.060 |
Why?
|
| Environmental Exposure | 3 | 1996 | 4528 | 0.060 |
Why?
|
| Patient Dropouts | 1 | 2007 | 411 | 0.060 |
Why?
|
| Occupational Exposure | 1 | 1994 | 1817 | 0.060 |
Why?
|
| Estrogens | 1 | 2010 | 1534 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 2296 | 0.050 |
Why?
|
| Body Burden | 3 | 1999 | 158 | 0.050 |
Why?
|
| Logistic Models | 3 | 2007 | 13323 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2010 | 1382 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 12558 | 0.050 |
Why?
|
| Multiple Chemical Sensitivity | 1 | 1999 | 7 | 0.040 |
Why?
|
| Humans | 28 | 2018 | 768393 | 0.040 |
Why?
|
| Hypertension | 2 | 1999 | 8615 | 0.040 |
Why?
|
| Dentin | 2 | 1996 | 75 | 0.040 |
Why?
|
| Anti-HIV Agents | 2 | 2008 | 4571 | 0.040 |
Why?
|
| Zidovudine | 1 | 2001 | 625 | 0.040 |
Why?
|
| Smoking | 2 | 2010 | 9111 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2017 | 65379 | 0.040 |
Why?
|
| Prognosis | 2 | 2008 | 30022 | 0.040 |
Why?
|
| Women | 1 | 1999 | 226 | 0.030 |
Why?
|
| Ohio | 2 | 1994 | 328 | 0.030 |
Why?
|
| Placebos | 1 | 2001 | 1668 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1996 | 80 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2018 | 6277 | 0.030 |
Why?
|
| Mortality | 1 | 2007 | 2917 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 10267 | 0.030 |
Why?
|
| Decision Making | 1 | 2010 | 3953 | 0.030 |
Why?
|
| Multivariate Analysis | 4 | 1999 | 12092 | 0.030 |
Why?
|
| Blood Pressure | 3 | 1996 | 8541 | 0.030 |
Why?
|
| Asthma | 1 | 1994 | 6280 | 0.030 |
Why?
|
| Weight Gain | 2 | 1996 | 2356 | 0.030 |
Why?
|
| Retirement | 1 | 1996 | 198 | 0.030 |
Why?
|
| Critical Illness | 1 | 2007 | 2755 | 0.030 |
Why?
|
| Time Factors | 3 | 2007 | 40272 | 0.030 |
Why?
|
| Erythropoiesis | 1 | 2017 | 693 | 0.030 |
Why?
|
| Growth | 1 | 1995 | 366 | 0.030 |
Why?
|
| Calcium, Dietary | 1 | 1996 | 533 | 0.030 |
Why?
|
| Hematocrit | 1 | 1994 | 625 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2007 | 10117 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 1994 | 436 | 0.030 |
Why?
|
| Nurses | 2 | 1999 | 2494 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 417 | 0.020 |
Why?
|
| Air Microbiology | 1 | 1992 | 95 | 0.020 |
Why?
|
| Exercise | 2 | 2018 | 5946 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 1995 | 1337 | 0.020 |
Why?
|
| Female | 13 | 2018 | 397089 | 0.020 |
Why?
|
| Fungi | 1 | 1992 | 345 | 0.020 |
Why?
|
| Educational Status | 1 | 1996 | 2518 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 876 | 0.020 |
Why?
|
| Middle Aged | 10 | 2017 | 223491 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2001 | 3080 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 1993 | 748 | 0.020 |
Why?
|
| Cross-Sectional Studies | 4 | 1996 | 26375 | 0.020 |
Why?
|
| Aging | 2 | 1996 | 8764 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6541 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 1995 | 2528 | 0.020 |
Why?
|
| Male | 11 | 2017 | 364902 | 0.020 |
Why?
|
| Obesity | 2 | 2018 | 13084 | 0.010 |
Why?
|
| Age Factors | 3 | 1996 | 18471 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 1996 | 2083 | 0.010 |
Why?
|
| Sample Size | 1 | 2007 | 848 | 0.010 |
Why?
|
| United States | 4 | 2007 | 73150 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1996 | 4049 | 0.010 |
Why?
|
| Data Collection | 1 | 2012 | 3324 | 0.010 |
Why?
|
| Kansas | 2 | 1993 | 37 | 0.010 |
Why?
|
| Statistics, Nonparametric | 2 | 2001 | 2862 | 0.010 |
Why?
|
| Child | 5 | 2018 | 80891 | 0.010 |
Why?
|
| Aged | 5 | 2017 | 171562 | 0.010 |
Why?
|
| Adult | 7 | 1996 | 223640 | 0.010 |
Why?
|
| Prevalence | 2 | 1994 | 15872 | 0.010 |
Why?
|
| Diet | 1 | 2018 | 8090 | 0.010 |
Why?
|
| Risk Factors | 4 | 2007 | 74962 | 0.010 |
Why?
|
| Solvents | 1 | 1999 | 298 | 0.010 |
Why?
|
| United States Department of Agriculture | 1 | 1995 | 47 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2001 | 2363 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 1996 | 59686 | 0.010 |
Why?
|
| Missouri | 1 | 1993 | 113 | 0.010 |
Why?
|
| Tennessee | 1 | 1993 | 123 | 0.010 |
Why?
|
| Wisconsin | 1 | 1993 | 122 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 12870 | 0.010 |
Why?
|
| Diet Surveys | 1 | 1996 | 1160 | 0.010 |
Why?
|
| Air Pollution, Indoor | 1 | 1999 | 915 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1995 | 12241 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 1992 | 1004 | 0.000 |
Why?
|
| Guidelines as Topic | 1 | 1995 | 1397 | 0.000 |
Why?
|
| Body Mass Index | 2 | 1995 | 13052 | 0.000 |
Why?
|
| Housing | 1 | 1992 | 680 | 0.000 |
Why?
|
| Adolescent | 4 | 1996 | 89184 | 0.000 |
Why?
|
| Boston | 1 | 1999 | 9371 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2007 | 24318 | 0.000 |
Why?
|
| Urban Population | 1 | 1993 | 2045 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 1996 | 2906 | 0.000 |
Why?
|
| Follow-Up Studies | 2 | 1996 | 39407 | 0.000 |
Why?
|
| Mass Screening | 1 | 1999 | 5451 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2001 | 20224 | 0.000 |
Why?
|
| Incidence | 1 | 1999 | 21544 | 0.000 |
Why?
|
| Prospective Studies | 2 | 1996 | 54920 | 0.000 |
Why?
|
| Massachusetts | 1 | 1993 | 8902 | 0.000 |
Why?
|
| Predictive Value of Tests | 1 | 1996 | 15455 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 1993 | 7861 | 0.000 |
Why?
|
| Sex Factors | 1 | 1993 | 10654 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1996 | 81801 | 0.000 |
Why?
|